It’s time for Congress to step up and fund America’s supply chain independence from Chinese companies by bolstering our ...

Oncternal Therapeutics will lay off about 10 workers as it explores “strategic alternatives” that could include asset sales ...

Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...

Analysts expressed skepticism about plans detailed by Moderna’s R&D chief Stephen Hoge to trim research spending in ...

BMO Capital Markets analyst Evan Seigerman said luvadaxistat’s inconsistencies between mid-stage trials raise questions about ...

In an effort to build its commercial capacity, Moderna on Thursday announced it is lowering research and development spending ...

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

Sanofi will join Big Pharma peers Novartis, BMS and Eli Lilly in radioligands, striking a $110 million licensing deal with ...

Terns Pharmaceuticals will advance TERN-601 into Phase II after early-stage data showed the oral therapy led to weight loss ...

Without revealing specific details, GSK announced that it is terminating the development of its investigational herpes ...

The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to ...